Clinical perspectives in drug safety and adverse drug reactions
- 1 September 2008
- journal article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 1 (5) , 695-705
Abstract
Adverse drug reactions (ADRs) remain a common clinical problem since they can mimic many diseases and cause significant morbidity and mortality. Judicious prescribing is important to minimize their occurrence. Apart from the recent identification of a few pharmacogenomic biomarkers for serious reactions, many remain unpredictable. Spontaneous reporting continues to play an important role in pharmacovigilance and the value of astute clinical observation and well-documented reports of suspicions of a causal link cannot be underestimated. Many national reporting schemes have developed considerable experience and expertise over many years and have large ADR databases, which are national assets. Despite advances in pharmacovigilance, numerous deficiencies have been identified; postmarketing surveillance remains the weakest link in the regulatory process. Regulatory authorities have tended to act later rather than sooner in response to safety signals, and this, when combined with under-reporting, may have led to exposure of a large number of patients to drug-related harm before restriction or withdrawal. In an attempt to improve vigilance, international surveillance may benefit by moving from its current passive/reactive mode toward active surveillance systems with a prospective, comprehensive and systematic approach to monitoring, collecting, analyzing and reporting data on ADRs. This will include increased pressure on pharmaceutical companies to conduct postmarketing studies. Such an active/proactive approach, while maintaining focus on ADR detection, could also aim to extend knowledge of safety, such that emerging changes in risk-benefit during a drug's marketed life are effectively communicated to clinicians and patients. Drug safety monitoring and its regulation are now undergoing an overhaul and it is hoped that vigilance, public safety and trust will improve as a result.Keywords
This publication has 103 references indexed in Scilit:
- Rosiglitazone and implications for pharmacovigilanceBMJ, 2007
- What have we learnt from Vioxx?BMJ, 2007
- Blueprint for a Stronger Food and Drug AdministrationNew England Journal of Medicine, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Impact Analysis of Signals Detected from Spontaneous Adverse Drug Reaction Reporting DataDrug Safety, 2005
- Physicians??? Attitudes and Adverse Drug Reaction ReportingDrug Safety, 2005
- Expecting the Unexpected — Drug Safety, Pharmacovigilance, and the Prepared MindNew England Journal of Medicine, 2004
- Pure Red-Cell Aplasia and Epoetin TherapyNew England Journal of Medicine, 2004
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- Reporting of adverse drug reactions by hospital doctors and the response to interventionBritish Journal of Clinical Pharmacology, 1997